Pomalidomide

Pomalidomide (INN, originally CC-4047 or 3-amino-thalidomide, trade name Pomalyst in the US and Imnovid in Europe) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma. It received a similar approval from the European Commission in August 2013.